Young adults diagnosed with advanced Hodgkin's lymphoma may no longer have to choose between survival and future parenthood. A major international study, published in The Lancet Oncology, shows that a new chemotherapy regimen, BrECADD, significantly improves fertility outcomes compared to the long-used eBEACOPP protocol — without compromising recovery rates. Led by researchers from University Hospital Cologne and the German Hodgkin Study Group (GHSG), the findings are poised to shift standard treatment guidelines for younger patients hoping to have children after cancer.
The results were published in The Lancet Oncology under the title "Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 Trial."
